乳腺癌新辅助治疗研究前景
Research Prospects for Neoadjuvant Treatment for Breast Cancer
DOI: 10.12677/ACM.2023.13102230, PDF,   
作者: 热娜姑丽·吾守尔, 孙祝生：新疆医科大学第五附属医院甲乳外科，新疆 乌鲁木齐；卜艾力·阿卜敦米吉提：新疆医科大学第五附属医院心血管内科，新疆 乌鲁木齐
关键词: 乳腺癌；新辅助治疗；内分泌治疗；靶向治疗；Breast Cancer； Neoadjuvant Therapy； Endocrine Therapy； Targeted Therapy
摘要: 近年来，乳腺癌新辅助治疗逐渐开始成为研究重点。新辅助治疗是在术前对患者进行系统治疗，相同方案和疗程的新辅助治疗与辅助治疗的效果是一样的。乳腺癌新辅助治疗方案的选择与分子分型密切相关，临床工作中，需要根据各型乳腺癌的分子生物学及临床特征选择合适的治疗方案。本文就不同分子分型乳腺癌的新辅助治疗进展进行综述。
Abstract: In recent years, the neoadjuvant therapy of breast cancer has gradually begun to become the focus of research. Neoadjuvant therapy is the systematic treatment of patients before surgery, and the effect of neoadjuvant therapy with the same regimen and course is the same as adjuvant therapy. The selection of neoadjuvant therapy for breast cancer is closely related to molecular classification. In clinical work, it is necessary to choose appropriate treatment options according to the molecular biology and clinical characteristics of each type of breast cancer. This review summarizes the pro-gress of neoadjuvant therapy in breast cancer with different molecular types.
文章引用：热娜姑丽·吾守尔, 卜艾力·阿卜敦米吉提, 孙祝生. 乳腺癌新辅助治疗研究前景[J]. 临床医学进展, 2023, 13(10): 15959-15963. https://doi.org/10.12677/ACM.2023.13102230

参考文献

[1] Wang, H. and Mao, X. (2020) Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Design, Development and Therapy, 14, 2423-2433. [Google Scholar] [CrossRef] 
[2] Akram, M., Iqbal, M., Daniyal, M. and Khan, A.U. (2017) Awareness and Current Knowledge of Breast Cancer. Biological Research, 50, Arti-cle No. 33. [Google Scholar] [CrossRef] [PubMed]
[3] 毕钊, 王永胜. 乳腺癌新辅助治疗后局部区域处理降阶梯策略[J]. 山东第一医科大学(山东省医学科学院)学报, 2023, 44(4): 249-253.
[4] Liu, Y.G., Wu, M.X., Tan, W.Y., et al. (2022) Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI. Contrast Media & Mo-lecular Imaging, 2022, Article ID: 4542288. [Google Scholar] [CrossRef] [PubMed]
[5] 毕钊, 王永胜. 乳腺癌新辅助治疗策略与手术时机[J]. 中国实用外科杂志, 2021, 41(11): 1220-1225.
[6] 艾宪程, 徐翔宇. HER-2阳性局部晚期乳腺癌新辅助靶向治疗的研究进展[J]. 当代医学, 2021, 27(23): 190-194.
[7] Shien, T. and Iwata, H. (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. Japanese Journal of Clinical Oncology, 50, 225-229. [Google Scholar] [CrossRef] [PubMed]
[8] Gallagher, K.K. and Ollila, D.W. (2019) Indications for Neoadjuvant Sys-temic Therapy for Breast Cancer. Advances in Surgery, 53, 271-292. [Google Scholar] [CrossRef] [PubMed]
[9] 陈安莉, 沈浩元, 王舒. 三阴性乳腺癌新辅助治疗的临床研究进展[J]. 现代肿瘤医学, 2023, 31(3): 566-571.
[10] Derakhshan, F. and Reis-Filho, J.S. (2022) Pathogenesis of Tri-ple-Negative Breast Cancer. Annual Review of Pathology, 17, 181-204. [Google Scholar] [CrossRef] [PubMed]
[11] Burstein, H.J., Curigliano, G., Loibl, S., et al. (2019) Estimating the Benefits of Therapy for Early-Stage Breast Cancer: The St. Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 30, 1541-1557. [Google Scholar] [CrossRef] [PubMed]
[12] Chaudhary, L.N., et al. (2018) Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy? Surgical Oncology Clinics of North America, 27, 141-153.
[13] Moore-Smith, L., Forero-Torres, A. and Stringer-Reasor, E. (2018) Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. The Surgical Clinics of North America, 98, 773-785. [Google Scholar] [CrossRef] [PubMed]
[14] 黄美玲, 李南林. 三阴性乳腺癌新辅助化疗中铂类的地位[J]. 医学争鸣, 2019, 10(3): 15-17.
[15] 何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[16] Sher, N.M., et al. (2022) Effects of Lipid Based Multiple Micronutrients Sup-plement on the Birth Outcome of Underweight Pre-Eclamptic Women: A Randomized Clinical Trial. Pakistan Journal of Medical Sciences, 38, 219-226. [Google Scholar] [CrossRef] [PubMed]
[17] Lin, Y.-Y., Gao, H.-F., Yang, X., et al. (2022) Neoadjuvant Therapy in Triple-Negative Breast Cancer: A Systematic Review and Network Meta-Analysis. Breast (Edinburgh, Scotland), 66, 126-135. [Google Scholar] [CrossRef] [PubMed]
[18] Obidiro, O., Battogtokh, G. and Akala, E.O. (2023) Triple Nega-tive Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics, 15, Article No. 1796. [Google Scholar] [CrossRef] [PubMed]
[19] 张磊. 三阴性乳腺癌新辅助化疗研究进展[J]. 中国处方药, 2021, 19(9): 21-22.
[20] 何建林, 梅振宇, 盛勇, 等. 三阴性乳腺癌新辅助治疗研究进展[J]. 中国肿瘤外科杂志, 2018, 10(5): 330-332.
[21] 张亚楠, 宋晓宇, 汪胤, 等. 乳腺癌新辅助治疗研究进展[J]. 癌症进展, 2022, 20(22): 2284-2288.

为你推荐